SHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sotera Health Co (SHC) is not a strong buy for a beginner, long-term investor at this moment. While the company shows positive financial growth and hedge funds are buying, the technical indicators and options data do not suggest a strong entry point currently. Additionally, the stock's short-term trend indicates potential downside in the next week.
The MACD is positive and contracting, suggesting mild bullish momentum. RSI is neutral at 39.275, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 15.297), but no strong breakout or reversal signal is present.
Hedge funds have significantly increased their buying activity by 140.83% over the last quarter. The company's Q4 2025 financials showed strong revenue growth (+4.56% YoY), net income growth (+182.91% YoY), and EPS growth (+200% YoY). Upcoming Q1 2026 earnings release and conference call may provide further insights.
Analyst sentiment is cautious, with Barclays lowering its price target to $18 from $20, citing risks in the life sciences sector. Short-term stock trend analysis suggests a potential -3.98% decline in the next week. No recent congress trading data or significant insider activity to support a strong buy signal.
In Q4 2025, Sotera Health reported revenue of $303.44M (+4.56% YoY), net income of $34.85M (+182.91% YoY), and EPS of $0.12 (+200% YoY). Gross margin improved to 53.68% (+4.56% YoY), reflecting strong operational performance.
Barclays recently lowered its price target to $18 from $20 but maintained an Overweight rating. Citi raised its price target to $23 from $21, citing prudent FY26 guidance with revenue growth expectations of 5%-6.5%.
